CA2966592C - Ocular delivery of drugs - Google Patents

Ocular delivery of drugs Download PDF

Info

Publication number
CA2966592C
CA2966592C CA2966592A CA2966592A CA2966592C CA 2966592 C CA2966592 C CA 2966592C CA 2966592 A CA2966592 A CA 2966592A CA 2966592 A CA2966592 A CA 2966592A CA 2966592 C CA2966592 C CA 2966592C
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
group
drug
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2966592A
Other languages
English (en)
French (fr)
Other versions
CA2966592A1 (en
Inventor
Ijeoma Uchegbu
Andreas Schatzlein
Lorenzo CAPRETTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanomerics Ltd
Original Assignee
Nanomerics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanomerics Ltd filed Critical Nanomerics Ltd
Publication of CA2966592A1 publication Critical patent/CA2966592A1/en
Application granted granted Critical
Publication of CA2966592C publication Critical patent/CA2966592C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2966592A 2014-11-03 2015-11-02 Ocular delivery of drugs Active CA2966592C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1419540.8 2014-11-03
GBGB1419540.8A GB201419540D0 (en) 2014-11-03 2014-11-03 Delivery of drugs
PCT/GB2015/053291 WO2016071677A1 (en) 2014-11-03 2015-11-02 Ocular delivery of drugs

Publications (2)

Publication Number Publication Date
CA2966592A1 CA2966592A1 (en) 2016-05-12
CA2966592C true CA2966592C (en) 2023-03-07

Family

ID=52118610

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2966592A Active CA2966592C (en) 2014-11-03 2015-11-02 Ocular delivery of drugs

Country Status (7)

Country Link
US (2) US10987304B2 (https=)
EP (1) EP3215119B1 (https=)
JP (1) JP6832276B2 (https=)
CN (2) CN116392600A (https=)
CA (1) CA2966592C (https=)
GB (1) GB201419540D0 (https=)
WO (1) WO2016071677A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
KR102810631B1 (ko) * 2018-02-26 2025-05-23 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 약물 전달 시스템
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
GB202007703D0 (en) 2020-05-22 2020-07-08 Nanomerics Ltd Amphiphilic carbohydrate compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
US6395756B2 (en) * 1999-12-23 2002-05-28 Novartis Ag Use of ophthalmic agent
DE10242080A1 (de) * 2002-09-11 2004-03-25 Degussa Ag Verfahren zur Katalysator-freien Herstellung von Cyanophenolen aus Methoxybenzonitrilen
GB0221941D0 (en) 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
GB0615834D0 (en) 2006-08-09 2006-09-20 Univ Glasgow Polymeric micellar clusters and their uses in formulating drugs

Also Published As

Publication number Publication date
US20210212938A1 (en) 2021-07-15
CN116392600A (zh) 2023-07-07
CA2966592A1 (en) 2016-05-12
EP3215119B1 (en) 2021-03-10
JP2017533228A (ja) 2017-11-09
JP6832276B2 (ja) 2021-02-24
EP3215119A1 (en) 2017-09-13
CN107106487A (zh) 2017-08-29
US10987304B2 (en) 2021-04-27
GB201419540D0 (en) 2014-12-17
US20170326064A1 (en) 2017-11-16
WO2016071677A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
Wang et al. Nano-in-Nano dendrimer gel particles for efficient topical delivery of antiglaucoma drugs into the eye
JP7455917B2 (ja) 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造
US20210212938A1 (en) Ocular delivery of drugs
Liu et al. Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: Prolonged ocular retention, enhanced corneal permeation and improved tear production
Zhang et al. Preparation and evaluation of naringenin-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles for ocular drug delivery
Li et al. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery
Elmowafy et al. Exploring optimized methoxy poly (ethylene glycol)-block-poly (ε-caprolactone) crystalline cored micelles in anti-glaucoma pharmacotherapy
He et al. In vitro and in vivo studies on ocular vitamin A palmitate cationic liposomal in situ gels
CA2946373C (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
JP6824270B2 (ja) 生物活性親油性化合物を有するｐｅｇ化脂質ナノ粒子
Sweeney et al. Impact of mucoadhesive agent inclusion on the intraocular pressure lowering profile of Δ9-tetrahydrocannabinol-valine-hemisuccinate loaded nanoemulsions in New Zealand white rabbits
CN113797164B (zh) 一种眼用制剂的载体或辅料及其制备方法和应用
HK1235697A1 (en) Ocular delivery of drugs
HK1235697B (en) Ocular delivery of drugs
Hu et al. Development and evaluation of cyclosporine a mixed micelle eye drops for enhanced ocular drug delivery
Jain et al. Niosomes encapsulated pilocarpine hydrochloride for ocular controlled delivery
Wu et al. In Situ Liquid Crystal Gel as a New Ophthalmic Drug Delivery System for Pilocarpine Nitrate: Improving Preocular Retention and Ocular Bioavailability
Lorenzo Veiga Cyclodextrin nanostructures and ocular drug delivery
Badr Topical Ocular Delivery to Posterior Eye Tissues
Maw Development of cyclodextrin-based pickering nanoemulsion containing amphotericin b for treatment of fungal keratitis
IT202100013787A1 (it) Composizione per l’uso nel trattamento di affezioni oculari, quali sindrome dell’occhio secco, specialmente post-chirurgico oftalmico / a composition for use in the treatment of ocular affections, such as dry eye disease, especially after eye surgery

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201007

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241030

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241030

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241030

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251015

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251015